WELCOME TO Million Health Pharmaceuticals

Brand : Geftinat
Ingredients : Gefitinib
Strength : 250mg
Manufactured : Natco
Package : 30 Tablets

dosage management

The suggested dosage of Geftinat tablets is 250mg should be administered orally as a single dose. The missed dose should not be taken within 12 hours of next dose.


Geftinat tablets are administered orally by taking with or without food. If patients are unable to take the tablets through mouth, must disperse tablets in a 4 to 8 ounces of water and mix it well, then drink the liquid immediately or taken via naso-gastric tube.

Dosage adjustment

Stop the Geftinat therapy, if patients have any of the following effects such as; Elevation of ALT & AST levels; Severe ocular disorders like keratitis High skin reactions Acute upraising or aggravation of pulmonary symptoms like cough, fever, dyspnea

Geftinat therapy should be discontinuing forever; in case of

Gastrointestinal perforation Interstitial lung disease Ulcerative keratitis Severe liver damage

Strong CYP3A4 inducers

In concomitant with strong CYP3A4 inducers, the dosage is increased to 500mg; continue the Geftinat therapy with 250mg after cessation of strong CYP3A4 inducers

unwanted effects

The adverse effect of Gefticip tablets

Liver toxicity Gastrointestinal perforation Severe diarrhea Bullous & expoliative skin disorders Ocular disorders Interstitial lung disease

Common side effects

Headache Diarrhea Fatigue Respiratory failure occurs due to pneumonia & pulmonary embolism Mucosal inflammation, tongue ulceration, eye irritation, eyelid Pruritus, edema Elevation of AST, ALT Proteinuria Hemorrhagic cystitis Cutaneous vasculitis Nausea Vomiting Skin reactions Nail disorders Stomatitis Loss of appetite Conjunctivitis Blepharitis Dry eye

Interstitial lung disease

Geftinat therapy is discontinued and immediately examine for ILD in any patients who have acute respiratory problems.

Liver toxicity

Patient getting Geftinat therapy, accidentally elevate AST & ALT levels and increased bilirubin levels leads to cause hepatotoxicity and to rescue from this condition discontinue the therapy.

Gastrointestinal perforation

Stop the Gefitinib therapy permanently.

Persistent diarrhea

Discontinue the Gefitinib therapy

Ocular disorders

Ocular disorders like corneal erosion, aberrant eyelash growth may occur during the therapy of Geftinat . To avoid this problem discontinue the Geftinat therapy.

Skin disorders

Skin disorders like Stevens Johnson’s syndrome, epidermal necrolysis & Erythema multiforme formed during the therapy. Geftinat therapy should be suspended or break off.

Embryo fetal toxicity

Gefitinib produce fetal harm, like fetotoxicity and neonatal death. Not recommended this therapy in pregnant women and use effective contraception methods.


Drug interaction

Geftinat tablet combined with strong CYP3A4 inducers like phenytoin, rifampicin, or tricyclic depressant may leads to decreasing the plasma concentration of Gefitinib because of increasing the metabolism. To avoid this problem, while concomitant with these drugs, the dosage of Geftinat is increased to 500mg, maintained by 250mg for 7 days after stopping the CYP3A4 inducers. Co administration of Geftinat with strong CYP3A4 inhibitors like itraconazole causes elevating the plasma concentration of Gefitinib due to decreasing in metabolism.

Geftinat combined with gastric regulator, causes depletion of plasma concentration of Gefitinib. Gastric regulators like proton pump inhibitors, H2 receptors antagonist, or antacids. Geftinat tablets are taken 12 hours after the last dose or 12 hours earlier to proton pump inhibitors; Geftinat tablets taken at 6 hours after or earlier to the dose of H2 receptor antagonist or antacids. Geftinat with warfarin leads to produce hemorrhage, to avoid this problem patients monitored frequently for prothrombin time alteration.

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.